{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:04:01Z","timestamp":1782446641776,"version":"3.54.5"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.intimp.2023.109774","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T12:00:22Z","timestamp":1678536022000},"page":"109774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Advances in the application of immune checkpoint inhibitors in gynecological tumors"],"prefix":"10.1016","volume":"117","author":[{"given":"YingGang","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoChen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianwen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.109774_b0005","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2023.109774_b0010","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.intimp.2023.109774_b0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.hoc.2014.02.002","article-title":"Immune checkpoint blockade","volume":"28","author":"Naidoo","year":"2014","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.intimp.2023.109774_b0025","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109774_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.021","article-title":"Immune checkpoints in the tumor microenvironment","volume":"65","author":"Toor","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.intimp.2023.109774_b0035","doi-asserted-by":"crossref","first-page":"e1398877","DOI":"10.1080\/2162402X.2017.1398877","article-title":"Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma","volume":"7","author":"Vermeulen","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2023.109774_b0040","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2023.109774_b0045","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2023.109774_b0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.intimp.2023.109774_b0055","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2023.109774_b0060","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1126\/science.282.5397.2263","article-title":"Molecular basis of T cell inactivation by CTLA-4","volume":"282","author":"Lee","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109774_b0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1074-7613(01)00097-8","article-title":"CTLA-4 regulates induction of anergy in vivo","volume":"14","author":"Greenwald","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2023.109774_b0070","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrd3463","article-title":"Ipilimumab","volume":"10","author":"Sondak","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2023.109774_b0075","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","article-title":"PD-L1 induced by IFN-\u03b3 from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer","volume":"22","author":"Zhang","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.imbio.2011.10.016","article-title":"Interferon-\u03b3-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway","volume":"217","author":"Chen","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.intimp.2023.109774_b0085","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3892\/ol.2020.11757","article-title":"Interferon-\u03b3 induced PD-L1 expression and soluble PD-L1 production in gastric cancer","volume":"20","author":"Imai","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.intimp.2023.109774_b0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.109774_b0095","first-page":"11","article-title":"Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities","author":"Rizzo","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2023.109774_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953115","article-title":"Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer","volume":"13","author":"Passarelli","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.109774_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072335","article-title":"Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions","volume":"21","author":"Kagabu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2023.109774_b0110","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109774_b0115","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3892\/mmr.2017.6102","article-title":"Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity","volume":"15","author":"Liu","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.intimp.2023.109774_b0120","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2015.108","article-title":"Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers","volume":"28","author":"Mezache","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.intimp.2023.109774_b0125","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.7150\/jca.22532","article-title":"PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer","volume":"9","author":"Meng","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.intimp.2023.109774_b0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CMAR.S152232","article-title":"The relationship between the PD-1\/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance","volume":"10","author":"Feng","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.intimp.2023.109774_b0135","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/modpathol.2016.221","article-title":"Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer","volume":"30","author":"Enwere","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.intimp.2023.109774_b0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13000-017-0631-6","article-title":"Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas","volume":"12","author":"Reddy","year":"2017","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.intimp.2023.109774_b0145","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11912-018-0740-8","article-title":"Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers","volume":"20","author":"Liu","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.intimp.2023.109774_b0150","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I\/II CheckMate 358 Trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0155","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0160","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0165","doi-asserted-by":"crossref","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2023.109774_b0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2012.00021","article-title":"Hypoxia promotes tumor growth in linking angiogenesis to immune escape","volume":"3","author":"Chouaib","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.109774_b0175","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0180","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.109774_b0185","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109774_b0190","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","article-title":"Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect","volume":"39","author":"Rodr\u00edguez-Ruiz","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2023.109774_b0195","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation; radiobiology or medicine?","volume":"26","author":"Mole","year":"1953","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.intimp.2023.109774_b0200","first-page":"499","article-title":"Abscopal effect of radiation on toruliform para-aortic lymph node metastases of advanced uterine cervical carcinoma\u2013a case report","volume":"27","author":"Takaya","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.intimp.2023.109774_b0205","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/1078-0432.CCR-17-3269","article-title":"Beyond Concurrent Chemoradiation: The Emerging Role of PD-1\/PD-L1 Inhibitors in Stage III Lung Cancer","volume":"24","author":"McCall","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.109774_b0210","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2023.109774_b0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics","volume":"80","author":"Prat","year":"2018","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.intimp.2023.109774_b0220","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0225","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109774_b0230","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109774_b0235","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109774_b0240","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0245","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0250","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/cas.14340","article-title":"Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100","volume":"111","author":"Nishio","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2023.109774_b0255","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0260","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0265","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0270","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174438","article-title":"Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives","volume":"13","author":"Maiorano","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2023.109774_b0275","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0280","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0285","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1136\/ijgc-2020-001694","volume":"30","author":"McMullen","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.intimp.2023.109774_b0290","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1016\/S1470-2045(13)70591-6","article-title":"Classification of endometrial carcinoma: more than two types","volume":"15","author":"Murali","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0295","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/PGP.0000000000000585","article-title":"Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer","volume":"39","author":"Yen","year":"2020","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.intimp.2023.109774_b0300","first-page":"1","article-title":"A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer","volume":"40","author":"Green","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.intimp.2023.109774_b0305","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.06.008","article-title":"Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?","volume":"48","author":"Gargiulo","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2023.109774_b0310","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109774_b0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0320","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1111\/cas.14148","article-title":"Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial","volume":"110","author":"Tamura","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2023.109774_b0325","first-page":"1135","article-title":"A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient\/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.intimp.2023.109774_b0330","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002255","article-title":"Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial","volume":"9","author":"Antill","year":"2021","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.intimp.2023.109774_b0335","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study","volume":"35","author":"Ott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0340","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0345","doi-asserted-by":"crossref","first-page":"90532","DOI":"10.18632\/oncotarget.20042","article-title":"Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity","volume":"8","author":"Mittica","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2023.109774_b0350","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0355","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0360","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1200\/EDBK_350541","article-title":"Novel Therapeutics in the Treatment of Uterine Sarcoma","volume":"42","author":"Bose","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.intimp.2023.109774_b0365","first-page":"12","article-title":"Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile","author":"Astolfi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2023.109774_b0370","doi-asserted-by":"crossref","unstructured":"Rizzo A, Nannini M, Astolfi A, Indio V, De Iaco P, Perrone AM, De Leo A, et al. Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis. Cancers (Basel) 2020;12.","DOI":"10.3390\/cancers12071899"},{"key":"10.1016\/j.intimp.2023.109774_b0375","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study","volume":"123","author":"Ben-Ami","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2023.109774_b0380","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2023.109774_b0385","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ctrv.2017.07.008","article-title":"Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives","volume":"59","author":"Ventriglia","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2023.109774_b0390","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11684-018-0674-4","article-title":"PD-1\/PD-L1 blockade in cervical cancer: current studies and perspectives","volume":"13","author":"Wang","year":"2019","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2023.109774_b0395","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0400","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41417-019-0131-9","article-title":"Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout","volume":"27","author":"Zhen","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.intimp.2023.109774_b0405","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2019.03.255","article-title":"Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?","volume":"154","author":"Lee","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2023.109774_b0410","first-page":"2514","article-title":"Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs","volume":"6","author":"Du Four","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2023.109774_b0415","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.1158\/1078-0432.CCR-16-1031","article-title":"Regression of Chemotherapy-Resistant Polymerase epsilon (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab","volume":"22","author":"Santin","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.109774_b0420","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923000978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923000978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:49:50Z","timestamp":1761587390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923000978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":84,"alternative-id":["S1567576923000978"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109774","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the application of immune checkpoint inhibitors in gynecological tumors","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109774"}}